Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kuehl Website

W. Michael Kuehl, M.D.

Selected Publications

1)  Bergsagel PL, Kuehl WM.
Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity.
Leukemia. 1-2, 2013.
2)  Kuehl WM, Bergsagel PL.
Molecular pathogenesis of multiple myeloma and its premalignant precursor.
J. Clin. Invest. 122: 3456-63, 2012.
3)  Kuehl WM.
Mouse models can predict cancer therapy.
Blood. 120: 238-40, 2012.
4)  Kuehl WM, Bergsagel PL.
MYC addiction: a potential therapeutic target in MM.
Blood. 120: 2351-2, 2012.
5)  Zingone A, Kuehl WM.
Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Semin. Hematol. 48: 4-12, 2011.
6)  Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O.
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Leuk. Lymphoma. 51: 2159-70, 2010.
7)  Dib A, Glebov OK, Shou Y, Singer RH, Kuehl WM.
A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line expresses only cyclin D1: yet both cyclin D1 and MYC are repositioned in close proximity to the 3'IGH enhancer.
DNA Repair (Amst.). 8: 330-5, 2009.
8)  Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM.
A monoclonal gammopathy precedes multiple myeloma in most patients.
Blood. 113: 5418-22, 2009.
9)  Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM.
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.
Cell. 137: 873-86, 2009.
10)  Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H.
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
Leukemia. 23: 2210-21, 2009.
11)  Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M.
OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.
Leuk. Res. 2009.
12)  McKenna R, Kyle R, Kuehl W, Grogan T, Harris N, Coupland R.
Plasma cell neoplasms. In: WHO Classification of Hematopoietic and Lymphoid Tumors.
Lyon, France: International Agency for Research on Cancer; 2008. p. 200-213 [Book Chapter]
13)  Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monographs. 25-31, 2008.
14)  Pichiorri F, Suh S, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM.
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
Proc. Natl. Acad. Sci. U.S.A. 105: 12885-90, 2008.
15)  Kuehl WM.
Modeling multiple myeloma by AID-dependent conditional activation of MYC.
Cancer Cell. 13: 85-7, 2008.
16)  Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD, Sawyer JR, Kuehl WM.
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
Genes Chromosomes Cancer. 47: 573-90, 2008.
17)  Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R.
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.
Leukemia. 22(2): 459-461, 2008.
18)  Bergsagel PL, Kuehl WM.
WSU-WM and BCWM.1 should not be assumed to represent Waldenström macroglobulinemia cell lines.
Blood. 112: 917, 2008.
19)  Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM.
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
J. Exp. Med. 204: 633-43, 2007.
20)  Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD.
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
Blood. 109: 4995-5001, 2007.
21)  Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM.
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Cancer Cell. 12: 115-30, 2007.
22)  Chng WJ, Glebov O, Bergsagel PL, Kuehl WM.
Genetic events in the pathogenesis of multiple myeloma.
Best practice & research. Clinical haematology. 20: 571-96, 2007.
23)  Dib A, Barlogie B, Shaughnessy JD, Kuehl WM.
Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma.
Blood. 109: 1337-8, 2007.
24)  Gabrea A, Bergsagel PL, Kuehl WM.
Distinguishing primary and secondary translocations in multiple myeloma.
DNA Repair. 5: 1225-1233, 2006.
25)  Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, Barlogie B, Shaughnessy J, Kuehl WM.
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.
Cell division. 1: 23, 2006.
26)  Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J.
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Blood. 106: 296-303, 2005.
27)  Bergsagel PL, Kuehl WM.
Molecular pathogenesis and a consequent classification of multiple myeloma.
J Clin Oncol. 23: 6333-8, 2005.
28)  Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM.
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
Blood. 105: 317-23, 2005.
29)  Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM.
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Cancer Cell. 5: 191-9, 2004.
30)  Kuehl WM, Bergsagel PL.
Multiple myeloma: evolving genetic events and host interactions.
Nat. Rev. Cancer. 2: 175-87, 2002.
Click Here to View Collapsed Bibliography.

This page was last updated on 11/21/2013.